Injection or Infusion?

When testing a novel drug compound in vivo via bolus injection, many researchers are unaware that plasma levels can greatly exceed effective concentrations, which may result in toxicity and ultimately wasting the compound. More importantly, using a compound with a short half-life can reduce its therapeutic impact.

This webinar will look at which method may be best suited for your testing and how infusion via an implantable device, such as ALZET^® Osmotic Pumps, may be a more suitable alternative. Find out how these devices can:

• Optimise the key determinants of drug action
• Increase efficacy and reduce side effects
• Support the 3Rs and save resources

Webinar presenter

Samantha Bazzell, MBA, BSc
Product Marketing Manager, ALZET
DURECT Corporation